We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

84 hedge funds and large institutions have $624M invested in Adaptimmune Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 21

0.11% less ownership

Funds ownership: 12.74% → 12.62% (-0.11%)

2% less capital invested

Capital invested by funds: $637M → $624M (-$13.3M)

3% less funds holding

Funds holding: 87 → 84 (-3)

11% less call options, than puts

Call options by funds: $982K | Put options by funds: $1.11M

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

Holders
84
Holders Change
-3
Holders Change %
-3.45%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
21
Closed
17
Calls
$982K
Puts
$1.11M
Net Calls
-$126K
Net Calls Change
-$589K

Top Buyers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$6.35M
2
Rafferty Asset Management
Rafferty Asset Management
New York
+$5.06M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.76M
4
OAMG
Odey Asset Management Group
United Kingdom
+$3.15M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.12M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$13.5M
2
Renaissance Technologies
Renaissance Technologies
New York
-$4.53M
3
Morgan Stanley
Morgan Stanley
New York
-$3.8M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$2.52M
5
PA
Perceptive Advisors
New York
-$2.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
76
Parallel Advisors
California
$4K -$1.09K -190 -21%
NFG
77
Next Financial Group
Texas
$3K – – –
CA
78
Clearstead Advisors
Ohio
$3K +$2.86K +500 New
Bank of Montreal
79
Bank of Montreal
Ontario, Canada
$3K +$3.78K +660 New
CG
80
Cutler Group
California
$2K – – –
CHA
81
Carmichael Hill & Associates
Maryland
$1K – – –
Daiwa Securities Group
82
Daiwa Securities Group
Japan
$1K – – –
ED
83
Exane Derivatives
France
$642 – – –
RCM
84
RA Capital Management
Massachusetts
– -$13.5M -2,499,025 Closed
Lord, Abbett & Co
85
Lord, Abbett & Co
New Jersey
– -$2.52M -466,668 Closed
PA
86
Perceptive Advisors
New York
– -$2.16M -400,000 Closed
Acadian Asset Management
87
Acadian Asset Management
Massachusetts
– -$1.63M -301,408 Closed
HS
88
HighVista Strategies
Massachusetts
– -$859K -159,351 Closed
AC
89
Athanor Capital
New York
– -$524K -97,240 Closed
ECM
90
ExodusPoint Capital Management
New York
– -$415K -76,920 Closed
Northern Trust
91
Northern Trust
Illinois
– -$270K -50,000 Closed
State of Tennessee, Department of Treasury
92
State of Tennessee, Department of Treasury
Tennessee
– -$255K -47,240 Closed
BIM
93
Bogle Investment Management
Massachusetts
– -$229K -42,515 Closed
JF
94
Jump Financial
Illinois
– -$215K -39,800 Closed
CPIG
95
Chicago Partners Investment Group
Illinois
– -$139K -24,870 Closed
SFS
96
Sowell Financial Services
Arkansas
– -$61K -11,286 Closed
ARTA
97
A.R.T. Advisors
New York
– -$56K -10,335 Closed
Deutsche Bank
98
Deutsche Bank
Germany
– -$3K -534 Closed
CFD
99
Creative Financial Designs
Indiana
– -$2K -400 Closed
ASN
100
Advisory Services Network
Georgia
– -$1K -170 Closed
1 2 3
4
5

ADAP Hedge Fund Activity: Q1 2021 in Review

84 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2021, worth a combined $624M — down 2.1% from $637M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of ADAP and 15 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 28 added.

The largest buyer was Baillie Gifford & Co, adding an estimated $6.35M. The largest seller was RA Capital Management, exiting entirely with an estimated $13.5M sold.

  • 84 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2021, down from 87 in Q4 2020.
  • Funds reported $624M of Adaptimmune Therapeutics stock for Q1 2021, down 2.1% quarter-over-quarter.
  • 15 funds opened new Adaptimmune Therapeutics positions in Q1 2021 and 17 closed out, a net change of -2 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2021 was Baillie Gifford & Co, an estimated $6.35M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q1 2021.